Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 14/20 | 1.00 |
| ▸ | HDAC3 | O15379 | 11/20 | 1.00 |
| ▸ | HDAC4 | P56524 | 11/20 | 1.00 |
| ▸ | HDAC1 | Q13547 | 11/20 | 1.00 |
| ▸ | HDAC7 | Q8WUI4 | 11/20 | 1.00 |
| ▸ | HDAC2 | Q92769 | 11/20 | 1.00 |
| ▸ | HDAC10 | Q969S8 | 11/20 | 1.00 |
| ▸ | HDAC11 | Q96DB2 | 11/20 | 1.00 |
| ▸ | HDAC8 | Q9BY41 | 11/20 | 1.00 |
| ▸ | HDAC6 | Q9UBN7 | 11/20 | 1.00 |
| ▸ | HDAC9 | Q9UKV0 | 11/20 | 1.00 |
| ▸ | HDAC5 | Q9UQL6 | 11/20 | 1.00 |
| ▸ | ERBB2 | P04626 | 11/20 | 1.00 |
| ▸ | EGFR | P00533 | 4/20 | 0.76 |
| ▸ | STK10 | O94804 | 1/20 | 0.70 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.70 |
| ▸ | ABL1 | P00519 | 1/20 | 0.70 |
| ▸ | YES1 | P07947 | 1/20 | 0.70 |
| ▸ | RET | P07949 | 1/20 | 0.70 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4903294 | 1.00 | KDR (1.00) | KDRHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL4902691 | 1.00 | KDR (1.00) | KDRHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL4902670 | 1.00 | KDR (1.00) | KDRHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL4903568 | 0.99 | KDR (1.00) | KDRHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL4903554 | 0.99 | KDR (1.00) | KDRHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL4897639 | 0.97 | KDR (1.00) | KDRHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL4897651 | 0.97 | KDR (1.00) | KDRHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL8212633 | 0.94 | HDAC3 (0.99) | KDRHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL4903781 | 0.94 | HDAC3 (0.99) | KDRHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL4741287 | 0.94 | HDAC3 (0.99) | KDRHDAC3HDAC4HDAC1HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240156825-A1 | USE OF SELECTIVE VEGFR2 AND FGFR1 INHIBITORS | FOUNTAIN THERAPEUTICS INC (US) | 2024-05-16 | — | — | US | disclosed |
| US-20080221132-A1 | Multi-Functional Small Molecules as Anti-Proliferative Agents | CURIS, INC. | 2008-09-11 | — | — | US | disclosed |
| US-20080221132-A1 | Multi-Functional Small Molecules as Anti-Proliferative Agents | CURIS, INC. | 2008-09-11 | — | — | US | disclosed |
| US-20080221132-A1 | Multi-Functional Small Molecules as Anti-Proliferative Agents | CURIS, INC. | 2008-09-11 | — | — | US | disclosed |
| WO-2008033747-A9 | MULTI-FUNCTIONAL SMALL MOLECULES AS ANTI-PROLIFERATIVE AGENTS | CURIS INC (MA) | 2008-07-24 | — | — | WO | disclosed |
| US-20080161320-A1 | FUSED BICYCLIC PYRIMIDINES AS PTK INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. | 2008-07-03 | — | — | US | disclosed |
| US-20080161320-A1 | FUSED BICYCLIC PYRIMIDINES AS PTK INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. | 2008-07-03 | — | — | US | disclosed |
| US-20080161320-A1 | FUSED BICYCLIC PYRIMIDINES AS PTK INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. | 2008-07-03 | — | — | US | disclosed |
| WO-2008033747-A2 | MULTI-FUNCTIONAL SMALL MOLECULES AS ANTI-PROLIFERATIVE AGENTS | CURIS, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
| WO-2008033745-A2 | FUSED BICYCLIC PYRIMIDINES AS PTK INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221132-A1 | Multi-Functional Small Molecules as Anti-Proliferative Agents | HDAC1, HDAC6, HDAC5 | KDR 2667/4885HDAC3 7/4885HDAC4 5/4885 |
| US-20240156825-A1 | USE OF SELECTIVE VEGFR2 AND FGFR1 INHIBITORS | FGFR1, FRS2, FGFR2 | KDR 5/4885HDAC3 1816/4885HDAC4 1801/4885 |
| US-20080161320-A1 | FUSED BICYCLIC PYRIMIDINES AS PTK INHIBITORS CONTAINING A ZINC BINDING MOIETY | HDAC1, HDAC2, BAZ2A | KDR 1887/4885HDAC3 32/4885HDAC4 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.